Table 2: Comparison of HDAM with Hyper-CVAD on Treatment Outcome

HDAM (n) CVAD (n)
No 52 21
Incidence of CR 87% (45) 76% (16) p=0.31
Failure with resistant disease 4% (2) 19% (4)
Deaths during induction 9% (5) 5% (1)
Time to CR (median days) 29 27
CR duration (median months) 34 18 p=0.86
Median survival (months) 21 27 p=0.73
3yr OS 35% 44%
5yr OS 30% NR

HDAM: high-dose AraC and Mitoxantrone; NR; not reached.